My SciELO
Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Revista Española de Enfermedades Digestivas
Print version ISSN 1130-0108
Abstract
ALVAREZ SUAREZ, B.; REVILLA NEGRO, J. de la; RUIZ-ANTORAN, B. and CALLEJA PANERO, J. L.. Hepatitis B reactivation and current clinical impact. Rev. esp. enferm. dig. [online]. 2010, vol.102, n.9, pp.542-552. ISSN 1130-0108.
Hepatitis B virus (HBV) reactivation results from increased viral replication in inactive carriers or patients with prior infection with HBV. Reactivation may occur spontaneously or secondary to immunomodulating or immunosuppressive chemotherapy. Reactivation may manifest with no symptoms but on occasion results in acute or even severe acute hepatitis. Prevention is the best management approach, hence HBV screening using serology should be performed for all patients undergoing any immunomodulating, immunosuppressive or chemotherapeutic treatment. Antiviral prophylaxis has proven effective in inactive carriers and in some patients with former infection with HBV undergoing selected immunosuppressive therapies.
Keywords : Hepatitis B; Immunosuppresive; AntiTNF; Chemotherapy; Prophylaxis.